Clinical Trial Update: Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the effectiveness and tolerability of tetracosactide (Synacthen) for post-dural puncture headaches was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-dural Puncture Headache

Drugs mentioned

• Synacthen (tetracosactide)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Post-dural Puncture Headache | Phase 2 | Status: TERMINATED